WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Related Keywords

Jan Davidson Moncada , European Hematology Association , World Health Organization , European Medicines Agency ,